12
Participants
Start Date
August 31, 2018
Primary Completion Date
September 1, 2021
Study Completion Date
September 1, 2021
BCMA-CS1 cCAR T cells
BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
RECRUITING
Chengdu Military General Hospital, Chengdu
RECRUITING
Peking University Shenzhen Hospital, Shenzhen
Lead Sponsor
Peking University Shenzhen Hospital
OTHER
Chengdu Military General Hospital
OTHER
iCAR Bio Therapeutics Ltd.
INDUSTRY
iCell Gene Therapeutics
INDUSTRY